Director: Pravin J. Mishra, PhD
Laboratory Manager: Tom Liu, PhD
Facilitating & accelerating the translational, precision medicine science & research to the clinical setting and back
The Solid Tumor Translational Science Shared Resource (STTSSR) team works closely with clinical and translational scientists to develop a customizable portfolio of biomarker assays in order to provide innovative, correlative science studies associated with early-phase solid tumor oncology clinical trials. This resource works closely with clinical investigators in the design and management of studies and provides guidance related to assay development and analysis. The STTSSR serves as a central repository for specimens collected from patients on trials and is responsible for processing the tissue for any number of downstream analyses. In addition to developing novel assays, the STTS-SR partners with otherShared Resources to utilize available technologies such as next-generation sequencing, RNA expression analysis and proteomics. In these situations, the STTSSR is responsible for obtaining and preparing the patient samples for downstream analyses and then collects and organizes the data.
The STTSSR resource also helps identify and develop partnerships among investigators and pharmaceutical companies to gain access to new drugs and compounds and to provide corresponding correlative testing and analyses for cancer studies.
- Develop and manage a strategic, correlative science plan for solid tumor clinical trials.
- Be a central laboratory for clinical trial specimen acquisition and processing.
- Provide project management for studies that utilize resources available through other OSUCCC Shared Resources, investigator laboratories and outside vendors.
- Develop a customizable portfolio of validated assays not available in other Shared Resources.
- Identify and help develop strategic partnerships among clinical investigators and appropriate pharmaceutical/biomedical companies.
Director: Pravin J. Mishra, MS, Ph.D.
Laboratory Manager: Tom Liu, MD, Ph.D.
Pravin J. Mishra, MS, PhD
Dr. Mishra has contributed significantly into innovative discoveries in oncology and molecular biology (basic, translational and clinical research). Dr. Mishra’s Career reflects success in academic, government, not-for-profit, start-up and healthcare settings. With over 14 years of experience, Dr. Mishra has excelled in discovery, leadership, operations, innovation and strategic new business development. Dr. Mishra has developed subject expertise in oncology, stem cells, cancer genomics, drug discovery and developmental therapeutics. He demonstrated commitment to scientific excellence and scientific rigor as evidenced by well documented international peer-reviewed publications, awards and presentations (>60). He handled key executive decision making (affecting ~$60M) successfully and promoted innovation in his previous companies/institutes. Dr. Mishra successfully led bioinformatics and data management teams at Intermountain healthcare to develop new informatics pipelines to handle big data and clinically relevant datasets. He coordinated, established and directed clinical genomics (accredited by CLIA and CAP) facility and founded R&D center at Intermountain Healthcare to facilitate translational research (bench-to-bedside) and to advance precision medicine efforts for the system. At National Cancer Institute (NCI)-National Institutes of Health (NIH), Dr. Mishra served as PI and co-investigator on a study to understand the mechanism involved in endoplasmic reticulum stress-mediated melanoma metastasis and the associated role of autophagy in cancer survival and resistance. At NCI using the various computational network and statistical analyses based on embryonic/developmental gene signature pattern (derived from embryonic melanocyte RNA-seq data), Dr. Mishra identified biomarkers that predicts late-stage melanoma patient survival. This research work was awarded - NCI Director’s Innovation award by Dr. Harold Varmus (Noble Laureate), Aflac Incorporated- American Association for Cancer Research (AACR) Scholar-in-Training Award. At Rutgers University, Dr. Mishra’s work demonstrated a critical role of mesenchymal stem cells in tumor development. He received several accolades for his work including New Jersey State award for excellence in cancer research. This study was later featured on cover page of cancer research journal and became a highly cited study. He also contributed in designing and assessing combination drug therapy against pancreatic cancer (patent: US20100240595). Dr. Mishra contributed in 5 additional patents in drug development, stem cell therapy and developing bioinformatics analytical models.
Xinglou (Tom) Liu, PhD
After several years practicing internal medicine in China, Dr. Liu obtained a PhD from the Department of Molecular Genetics at The Ohio State University, with a dissertation focused on the development of viral vectors for gene therapy. He continued his training at Ohio State with a postdoctoral fellowship studying molecular, cellular and tumor immunology. Subsequently, Dr. Liu took a research scientist position at the department of Human Cancer Genetics at Ohio State, with his research focused on the manipulation of cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs) in small animal models, and development of a novel vaccine against the EBV-associated post-transplant lymphoproliferative disorders (PTLD). In 2011, he joined the Solid Tumor Translational Science Shared Resource as a senior research associate and lab manager. Dr. Liu has been instrumental in establishing the STTS-SR laboratory and the standard procedure for the purification of analytes (RNA/DNA/protein) from a variety of clinical specimens. In addition to overseeing the day-to-day operations of the lab and specimen handling, his efforts include the development and implementation of novel biomarker assays. To date, Dr. Liu has become an expert at several methods for next-generation sequencing library preparation, mRNA and miRNA in situ hybridization and the analysis of mutations in circulating tumor DNA purified from patient plasma samples.